In the surveillance, epidemiology, and end results (SEER)-Medicare database population study, women over 67 years with breast cancer had no significant differences in MI risk when treated with tamoxifen and aromatase inhibitors [135]. The gene discussed is CYP19A1; the disease is breast cancer.